Identification of genetic biomarkers in urine for early detection of prostate cancer

Eyyup Kavalci, Ali Ulvi Onder, Klaus Brusgaard, Aysegul Bostanci, Mehmet Yavuz Selhanoglu, Nedime Serakinci*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review


Prostate cancer screening is a challenging and vital issue in the aspects of the current tests and risk assessments. Prostate cancer risk assessments are currently carried out by using blood, urine and tissue biomarkers with radiological imaging methods. Here, we introduce a novel noninvasive screening tool for a further in-depth selection of eligible cases for prostate biopsies which is based on sequencing somatic and hereditary HOXB13 mutations in urine samples. This approach provides diagnostic information to the physician about the presence of prostate cancer while aiming to screen for specific prostate biopsies and save biopsies potentially when there are no mutations related to prostate cancer. Findings suggest that this method is reliable, cost-effective, and has a promising potential in prostate cancer screening.

Original languageEnglish
Article number100616
JournalCurrent Problems in Cancer
Issue number1
Publication statusPublished - Feb 2021


  • Biomarkers
  • HOXB13
  • Prostate cancer
  • Prostate cancer screening
  • Urine


Dive into the research topics of 'Identification of genetic biomarkers in urine for early detection of prostate cancer'. Together they form a unique fingerprint.

Cite this